Spyglass
Payments companies reported to CMS as associated with Spyglass. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Spyglass, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Spyglass
These are the largest totals companies reported as associated with Spyglass. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Isaac Raijman | Houston, TX | Gastroenterology (Internal Medicine) | $62,447.53 |
| David Forcione | Boston, MA | Gastroenterology (Internal Medicine) | $18,875.00 |
| Harshit Khara | Danville, PA | Gastroenterology (Internal Medicine) | $18,479.21 |
| Ara Sahakian | Los Angeles, CA | Gastroenterology (Internal Medicine) | $17,073.49 |
| James Buxbaum | Los Angeles, CA | Gastroenterology (Internal Medicine) | $16,827.82 |
| Venkataraman Muthusamy | Los Angeles, CA | Gastroenterology (Internal Medicine) | $13,930.61 |
| Jennifer Phan | Newport Beach, CA | Gastroenterology (Internal Medicine) | $13,629.10 |
| Neil Sharma | Gilbert, AZ | Gastroenterology (Internal Medicine) | $11,007.77 |
| Veeral Oza | Greenville, SC | Gastroenterology (Internal Medicine) | $10,217.22 |
| Sumit Singla | Detroit, MI | Gastroenterology (Internal Medicine) | $7,613.36 |
Prescribed Spyglass?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.